GURU.Markets stock price, segment price, and overall market index valuation
The company's share price IDEAYA Biosciences
IDEAYA Biosciences is an oncology company specializing in synthetic lethality. Its stock price reflects the potential of its targeted drugs. Its stock price, typical of biotech companies, is driven by news of clinical trials and partnerships with major pharma.
Share prices of companies in the market segment - Oncology targeted therapy
IDEAYA is a biotech company specializing in precision oncology, specifically synthetic lethality. We classify it in the Oncology Targeted Therapy sector, and the chart below shows the general dynamics of biotech companies, where value is determined by the success of clinical data.
Broad Market Index - GURU.Markets
IDEAYA Biosciences is an oncology company focused on developing targeted therapies for patients with specific genetic biomarkers. Its approach to personalized medicine makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how IDEAYA compares to it.
Change in the price of a company, segment, and market as a whole per day
IDYA - Daily change in the company's share price IDEAYA Biosciences
IDEAYA Biosciences, an oncology company, has experienced extreme volatility. Change_co measures market reaction to clinical trial data in the field of targeted therapy. This metric is an essential component in building valuation models for companies at the forefront of science on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
IDEAYA Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IDYA's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
IDEAYA Biosciences is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating IDEAYA shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization IDEAYA Biosciences
IDEAYA is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted cancer treatments based on genetic markers. Its approach is based on synthetic lethality. The chart shows how the market values its innovative scientific platform and partnerships with major pharmaceutical companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
IDEAYA Biosciences is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization IDEAYA Biosciences
IDEAYA, a biotech company specializing in targeted cancer therapy, has sharp monthly fluctuations reflecting news about clinical trials of its drugs, especially in partnership with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Targeted oncology biotechnology is at the forefront of science in the fight against cancer. The market capitalization dynamics of this sector, visible on the chart, reflect investors' faith in scientific breakthroughs and personalized medicine. This is the environment where innovators like IDEAYA Biosciences conduct their research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
IDEAYA Biosciences is an oncology company focused on targeted therapy. Its shares operate in their own information space: scientific publications and trial data determine their trajectory. They can rise when the market declines, and vice versa, demonstrating complete independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization IDEAYA Biosciences
IDEAYA Biosciences is an oncology company specializing in targeted therapies and synthetic lethality. Its weekly stock price is highly volatile, driven by the release of clinical trial data and news of partnerships with major pharmaceutical companies to develop its drugs.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
IDEAYA, as a clinical-stage biotech, exists in its own universe. Its weekly performance is 100% dependent on clinical trial news, not on general trends in the pharmaceutical industry. The chart clearly demonstrates these sharp, sector-neutral ups and downs, typical of biotechs on the cusp of breakthroughs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
IDEAYA Biosciences is an oncology company working in the promising field of synthetic lethality. Its shares are a bet on a scientific breakthrough. The chart clearly shows their extreme volatility and complete dependence on news about clinical trials.
Market capitalization of the company, segment and market as a whole
IDYA - Market capitalization of the company IDEAYA Biosciences
IDEAYA Biosciences' market capitalization dynamics reflect investors' faith in its approach to targeted cancer therapy, specifically the concept of synthetic lethality. As a clinical-stage company, its price is highly volatile, driven by news of partnerships with major pharma and clinical trial data. This represents a high-risk bet on cutting-edge science.
IDYA - Share of the company's market capitalization IDEAYA Biosciences within the market segment - Oncology targeted therapy
IDEAYA Biosciences is a biotechnology company focused on targeted oncology therapy. Its market share is based on its synthetic lethality approach, and its market capitalization reflects the potential of its developments in treating genetically defined cancers.
Market capitalization of the market segment - Oncology targeted therapy
Below is a chart of the overall biotech sector market capitalization. IDEAYA Biosciences is a leading example of synthetic lethality in oncology. This is a cutting-edge approach to creating targeted drugs. The potential of this market is enormous, and IDEAYA, often in partnership with giants, is at the forefront of this scientific revolution.
Market capitalization of all companies included in a broad market index - GURU.Markets
IDEAYA Biosciences is a biotech company focused on "synthetic lethality"—a new approach to cancer treatment. Its market capitalization is a bet on breakthroughs in personalized oncology. The chart below shows the economic weight of cutting-edge scientific concepts in medicine.
Book value capitalization of the company, segment and market as a whole
IDYA - Book value capitalization of the company IDEAYA Biosciences
IDEAYA Biosciences' foundation is its intellectual property in a portfolio of targeted oncology therapies based on the concept of synthetic lethality. The chart is a financial timeline of the biotech company, showing how successful early clinical trial results attract capital, strengthening its balance sheet for further research.
IDYA - Share of the company's book capitalization IDEAYA Biosciences within the market segment - Oncology targeted therapy
IDEAYA Biosciences develops targeted therapies for cancer treatment. The chart shows its share of actual R&D assets. These are its research laboratories, where research is conducted to create drugs that target genetic vulnerabilities in tumors.
Market segment balance sheet capitalization - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on synthetic lethality. Its model is intellectually, not capital-intensive. The company's value lies in its platform and partnerships, not its manufacturing plants. Compared to the biotech sector, its "light" balance sheet is typical of companies at the forefront of science.
Book value of all companies included in the broad market index - GURU.Markets
IDEAYA Biosciences' assets are not drugs, but a portfolio of promising molecules for targeted cancer therapy. The company's balance sheet reflects the value of its scientific discoveries and partnerships with pharmaceutical giants. The chart shows how much capital is invested in cutting-edge oncology aimed at targeted tumor destruction.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - IDEAYA Biosciences
IDEAYA Biosciences is an oncology company focused on developing targeted therapies. Its market capitalization reflects the hopes for its scientific platform, not its asset value. Investors are buying a stake in a potential breakthrough in cancer treatment, and the chart shows how this hope fluctuates based on news and research data.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on targeted therapy. Its value is derived from the potential of its scientific developments. This chart clearly demonstrates how its market capitalization, based on its belief in the future success of its drugs, greatly exceeds the modest value of its laboratories.
Market to book capitalization ratio for the market as a whole
IDEAYA Biosciences is an oncology company developing targeted therapies. Its value is almost entirely determined by the potential of its scientific developments and partnerships with major pharmaceutical companies. This chart demonstrates how biotech market valuations are based on future scientific breakthroughs rather than current assets.
Debts of the company, segment and market as a whole
IDYA - Company debts IDEAYA Biosciences
IDEAYA Biosciences is an oncology company specializing in targeted therapies and synthetic lethality. Developing such precision-engineered drugs requires massive investments in genomic research and clinical trials. This chart shows how the company is raising capital to fund its cutting-edge scientific platform.
Market segment debts - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in targeted therapies. Debt is rare in biotech at the R&D stage, and its presence can indicate the maturity of developments or partnerships. This chart shows the funding path IDEAYA has chosen for its research, which is an important indicator of its progress and confidence in its scientific platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio IDEAYA Biosciences
IDEAYA Biosciences is a biotech company specializing in targeted therapies and synthetic lethality for cancer treatment. This chart shows its financial position at the clinical stage. The absence of debt and reliance on equity and partnership payments are typical of companies whose value is based on the potential of their innovative scientific approach.
Market segment debt to market segment book capitalization - Oncology targeted therapy
IDEAYA Biosciences is a biotech company focused on targeted oncology therapies. This chart shows the level of leverage in the precision oncology research sector. It gives investors an idea of how the company's research funding strategy is typical for an industry where scientific breakthroughs require massive investments.
Debt to book value of all companies in the market
IDEAYA Biosciences is a biotech company whose future depends on scientific breakthroughs. This chart shows the debt burden for the entire economy. It serves as a reminder that there are entire sectors, like biotech, whose financial fate is decided in laboratories, not in the debt markets reflected in the chart.
P/E of the company, segment and market as a whole
P/E - IDEAYA Biosciences
For IDEAYA Biosciences, which focuses on targeted cancer therapy, this chart is an assessment of its scientific approach. The very high price per dollar of potential revenue suggests that investors see enormous potential in its research. The metric's dynamics reflect progress in clinical trials and news of partnerships with major pharma.
P/E of the market segment - Oncology targeted therapy
This chart reflects the average valuation for the speculative biotech sector—a benchmark for IDEAYA. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism. This provides a useful backdrop for assessing expectations for IDEAYA's developments in targeted cancer therapy.
P/E of the market as a whole
IDEAYA Biosciences is developing targeted oncology therapies that target specific genetic mutations in tumors. This cutting-edge science requires investor confidence. This chart of overall risk sentiment shows the market's willingness to fund such long-term research projects. During periods of optimism, investors see potential; during downturns, they see risks.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company IDEAYA Biosciences
IDEAYA Biosciences is an oncology company specializing in targeted therapies that target specific genetic mutations in tumors. Its valuation is based on the potential of its scientific developments. This chart shows the analysts' confidence that clinical trials will be successful and lead to the development of new, effective cancer treatments.
%20P%2FE%20IDEAYA%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-IDEAYA-Biosciences&v=1772513693027 "Chart of the company's future (projected) P/E IDEAYA Biosciences")
Future (projected) P/E of the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. Its valuation, relative to other oncology biotechs, reflects the high expectations for its scientific platform. This premium valuation reflects investors' confidence in its ability to develop breakthrough treatments for difficult-to-treat cancers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513693048 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
IDEAYA Biosciences is an oncology company specializing in targeted therapies based on the principles of synthetic lethality. Its shares represent an investment in cutting-edge science. This chart reflects the market's overall risk appetite. During periods of optimism, investors are more willing to invest in high-risk but potentially breakthrough biotech companies like IDEAYA.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513693056 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit IDEAYA Biosciences
IDEAYA Biosciences is an oncology company focused on targeted therapy and synthetic lethality. Its financial metrics, as reflected here, primarily reflect investments in research and clinical trials. Partnerships with major pharmaceutical companies and successful drug data drive its valuation and future prospects.
Profit of companies in the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on targeted therapy, selecting drugs based on the genetic characteristics of tumors. This chart reflects the financial health of the oncology biotech sector and demonstrates the commercial success of personalized medicine in the fight against cancer.
Overall market profit
IDEAYA Biosciences develops targeted cancer therapies based on a synthetic lethality approach. This is a science-intensive field, where a company's value is determined by the potential of its developments. The macroeconomic backdrop, reflected in this chart, influences investor sentiment, but clinical trial data and partnerships are fundamentally important to IDEAYA.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company IDEAYA Biosciences
IDEAYA Biosciences is a biotech company focused on developing targeted therapies for cancer treatment based on genetic markers. Its future revenue projections are a long-term bet on the success of its approach to personalized oncology. This chart reflects analysts' confidence in the company's scientific platform and its partnerships with major pharma companies.
%20profit%20of%20the%20company%20IDEAYA%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-IDEAYA-Biosciences&v=1772513693155 "Graph of future (projected) profit of the company IDEAYA Biosciences")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
IDEAYA Biosciences is a biotech company specializing in targeted oncology therapy. It develops drugs that target specific genetic mutations in tumors using a synthetic lethality approach. This chart shows forecasts for this segment, illustrating the enormous expectations for personalized medicine in the fight against cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513693163 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. This graph, reflecting profit expectations, influences investors' appetite for risky assets. During periods of economic growth, capital is more willing to flow into the biotech sector, funding long-term research that leads to breakthroughs in cancer treatment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513693177 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - IDEAYA Biosciences
IDEAYA Biosciences specializes in targeted oncology therapies, developing drugs for patients with specific genetic mutations. While revenue is minimal, this figure reflects pure expectations. Investors evaluate the scientific potential of its developments and the size of future markets for its drugs.
P/S market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in targeted therapies that target genetic mutations in cancer cells. This chart reflects the average valuation in the biotech sector. It shows the premium investors are willing to pay for companies developing personalized cancer treatment approaches with high potential effectiveness.
P/S of the market as a whole
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality, an approach that kills only cancer cells. The company's revenue potential is enormous, but it depends on the success of clinical trials. This chart serves as a contrast, showing how the market values actual revenue today versus potential revenue tomorrow.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company IDEAYA Biosciences
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. Its valuation is based on the future potential of its development pipeline. This chart demonstrates the extent to which investors believe in the company's scientific approach and its ability to create drugs that will revolutionize cancer treatment and generate billions in revenue.
%20P%2FS%20IDEAYA%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-IDEAYA-Biosciences&v=1772513693261 "The graph of the company's future (projected) P/S IDEAYA Biosciences")
Future (projected) P/S of the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in targeted therapies based on the concept of synthetic lethality. This allows the destruction of cancer cells with specific genetic mutations. This chart shows how investors view the potential of this cutting-edge scientific approach compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513693267 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
This reflects investors' faith in breakthroughs in oncology. For IDEAYA Biosciences, a company developing targeted cancer therapy based on synthetic lethality, this reflects risk appetite. Market optimism creates favorable conditions for funding cutting-edge research that could lead to the development of a new class of anti-cancer drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513693298 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales IDEAYA Biosciences
IDEAYA Biosciences is an oncology company specializing in targeted therapies based on the principles of synthetic lethality. This chart reflects revenue from partnerships with major pharmaceutical companies for co-development of drugs. In the future, it will show revenue from sales of drugs targeting specific genetic mutations in tumors.
Sales of companies in the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in targeted therapies and synthetic lethality. This chart illustrates the growth of the targeted cancer therapy market. IDEAYA is at the forefront of personalized medicine, developing treatments for patients with specific genetic mutations, reflecting the future of oncology.
Overall market sales
IDEAYA Biosciences is an oncology company focused on targeted therapies. Its development is entirely dependent on the success of clinical trials and partnerships with major pharmaceutical companies. The overall economic situation, shown in this chart, indirectly influences the funding available for risky but potentially breakthrough biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company IDEAYA Biosciences
IDEAYA Biosciences is an oncology company focused on synthetic lethality, an approach that exploits the genetic vulnerabilities of cancer cells. Future revenue depends on the success of its clinical programs. This chart reflects analysts' assessments of the scientific potential and commercial prospects of the targeted drugs the company is developing for precision cancer treatment.
%20sales%20of%20the%20company%20IDEAYA%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-IDEAYA-Biosciences&v=1772513693360 "Schedule of future (projected) sales of the company IDEAYA Biosciences")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on targeted therapies that target specific genetic mutations in cancer cells. This forecast reflects expectations for the entire targeted oncology therapy sector. It highlights the enormous growth potential analysts see in personalized cancer treatment, where IDEAYA excels.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513693374 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
IDEAYA Biosciences is an oncology company specializing in targeted therapy and precision medicine. Its growth depends on successful clinical trials and partnerships. The overall economic environment, reflected in this chart, influences venture capital flows into the biotech sector, which is necessary to finance long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513693387 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality IDEAYA Biosciences
IDEAYA Biosciences develops targeted therapies for cancer treatment, selecting drugs for specific genetic mutations. The graph illustrates the intensive research stage. Negative values do not represent losses, but rather targeted investments in clinical trials, the success of which determines the development of breakthrough oncology drugs.
Market segment marginality - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. Currently in clinical trials, profitability is a future goal. This metric reflects the structure of its research investments and allows for comparison of its operating model with other oncology biotech companies.
Market marginality as a whole
IDEAYA Biosciences is an oncology company focused on targeted therapy and precision medicine. This total market profitability graph is irrelevant to its operating performance. IDEAYA's future profitability depends entirely on breakthrough scientific discoveries, clinical trial results, and the company's ability to develop treatments for genetically defined patient groups.
Employees in the company, segment and market as a whole
Number of employees in the company IDEAYA Biosciences
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. This chart shows the company's growing team of scientists and clinicians. This growth in staff is a direct indicator of progress in the development of new anticancer drugs and the expansion of clinical programs.
Share of the company's employees IDEAYA Biosciences within the market segment - Oncology targeted therapy
IDEAYA Biosciences develops targeted therapies for oncology based on the principles of synthetic lethality. This chart shows the percentage of leading biologists and translational medicine specialists the company attracts in this cutting-edge field. It reflects its concentration of intellectual capital for the creation of next-generation cancer drugs.
Number of employees in the market segment - Oncology targeted therapy
IDEAYA Biosciences, Inc. is an oncology company focused on targeted therapy and precision medicine. It develops drugs that target genetic mutations in cancer cells using a synthetic lethality approach. This chart depicts employment in the targeted oncology sector, illustrating how breakthroughs in cancer genetics are creating new treatment opportunities and jobs for scientists.
Number of employees in the market as a whole
IDEAYA Biosciences is an oncology company focused on targeted therapy based on synthetic lethality. It is at the forefront of medical science. Its market capitalization and staff reflect not current revenue, but rather investors' faith in future breakthroughs. Such companies are growth engines, creating jobs for top-notch scientists and changing the quality of life.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company IDEAYA Biosciences (IDYA)
IDEAYA Biosciences is an oncology company specializing in targeted therapy and synthetic lethality. This chart is a classic example of a biotech startup. The astronomical market capitalization per employee reflects investors' faith in the company's scientific approach, which could lead to the creation of breakthrough cancer treatments.
%20of%20the%20company%20IDEAYA%20Biosciences%20(IDYA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-IDEAYA-Biosciences-IDYA&v=1772513693513 "Chart of market capitalization per employee (in thousands of dollars) of the company IDEAYA Biosciences (IDYA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in "synthetic lethality"—an approach that exploits the genetic vulnerabilities of cancer cells. It's an R&D-focused biotech company. This chart shows the average market capitalization per employee in the sector. It helps assess the market premium placed on their high-tech scientific platform per scientist.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513693548 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
IDEAYA Biosciences is an oncology company specializing in targeted therapies and biomarkers. This chart shows the market-wide valuation of one employee, illustrating the enormous value the market places on the potential of breakthrough cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513693563 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company IDEAYA Biosciences (IDYA)
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. It's at the cutting edge of science. The company is in the clinical stage, so this chart shows the loss per employee. It reflects the cost of R&D and the stake investors are placing on IDEAYA's research team.
%20Chart%20IDEAYA%20Biosciences%20(IDYA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-IDEAYA-Biosciences-IDYA&v=1772513693574 "Company Profit Per Employee (in thousands of dollars) Chart IDEAYA Biosciences (IDYA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
IDEAYA (IDYA) is an R&D biotech company (oncology, "synthetic lethality"). This chart shows the benchmark for "Oncology" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513693575 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
IDEAYA Biosciences is an oncology company specializing in targeted therapy and "synthetic lethality." It's a cutting-edge R&D company. Like other clinical-stage biopharma companies, it's not profitable. This chart reflects the cost of science: the operating loss per team of scientists searching for new ways to fight cancer based on patient genetics.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513693593 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee IDEAYA Biosciences (IDYA)
IDEAYA Biosciences is an oncology company focused on targeted therapy. For a biotech company in clinical development, this chart is primarily an indicator of potential. It reflects the company's future ability to generate massive revenues from the sale of innovative drugs created by a small team of scientists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-IDEAYA-Biosciences-IDYA&v=1772513693609 "Sales chart per company employee IDEAYA Biosciences (IDYA)")
Sales per employee in the market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company focused on targeted therapies and synthetic lethality. It boasts deep R&D capabilities. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of IDEAYA's scientific team within the industry context.
Sales per employee for the market as a whole
IDEAYA Biosciences is a clinical-stage biotechnology company specializing in targeted cancer therapy. The company has no approved products or commercial revenue. This metric is currently irrelevant. The company's entire value lies in its R&D platform and the potential of its team of scientists to create new drugs.
Short shares by company, segment and market as a whole
Shares shorted by company IDEAYA Biosciences (IDYA)
IDEAYA Biosciences is a biotech company focused on "synthetic lethality," a promising approach to cancer treatment. The company is in the clinical stage. This chart reflects high risk: investors are betting that promising early data will not be confirmed in larger trials, or that competitors will be faster.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-IDEAYA-Biosciences-IDYA&v=1772513693620 "Short Shares Chart for the Company IDEAYA Biosciences (IDYA)")
Shares shorted by market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in targeted therapy and the principle of "synthetic lethality." They aim to treat cancer by exploiting specific genetic vulnerabilities in tumors. This chart reflects the total volume of short positions in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials in oncology.
Shares shorted by the overall market
IDEAYA (IDYA) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives IDYA of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator IDEAYA Biosciences (IDYA)
IDEAYA Biosciences (IDYA) is an oncology company specializing in "synthetic lethality," an approach in which drugs target the genetic vulnerabilities of cancer cells. This chart measures hype. It shows "overbought" (above 70) during promising clinical trial data or "oversold" (below 30) during periods of anticipation and high uncertainty, typical of biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-IDEAYA-Biosciences-IDYA&v=1772513693638 "RSI 14 indicator chart for the company's stock IDEAYA Biosciences (IDYA)")
RSI 14 Market Segment - Oncology targeted therapy
IDEAYA Biosciences (IDYA) is an oncology company specializing in "synthetic lethality." They create targeted drugs that kill cancer cells with specific genetic mutations. This chart measures the overall sentiment in the Targeted Oncology sector. It helps distinguish IDYA's development successes from the overall "overheated" or "oversold" biotech sector.
RSI 14 for the overall market
IDEAYA Biosciences (IDYA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IDYA (IDEAYA Biosciences)
IDEAYA Biosciences is a biotech company focused on "synthetic lethality"—a cutting-edge approach in oncology for creating targeted therapies based on tumor genetics. This chart shows the average analyst price target, based on the potential of its research portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IDYA-IDEAYA-Biosciences&v=1772513693654 "A chart showing analyst consensus forecasts for the expected stock price. IDYA (IDEAYA Biosciences)")
The difference between the consensus estimate and the actual stock price IDYA (IDEAYA Biosciences)
IDEAYA Biosciences (IDYA) is an oncology company specializing in synthetic lethality. This is a cutting-edge approach to targeted therapy that attacks the weak points of cancer cells. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their scientific approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IDYA-IDEAYA-Biosciences&v=1772513693658 "A chart showing the difference between the consensus forecast and the actual stock price. IDYA (IDEAYA Biosciences)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
IDEAYA Biosciences is an oncology company specializing in "synthetic lethality"—an approach that kills cancer cells by exploiting their genetic vulnerabilities. This chart shows the overall expectations for the targeted oncology sector, reflecting experts' confidence in this cutting-edge cancer treatment method.
Analysts' consensus forecast for the overall market share price
IDEAYA Biosciences (IDYA) is a cutting-edge biotech developing targeted therapies for cancer (synthetic lethality). This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to fund unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and R&D capital dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index IDEAYA Biosciences
IDEAYA Biosciences is a biotech company working in the hot field of synthetic lethality in oncology. They develop targeted drugs that attack cancer by exploiting its specific genetic vulnerabilities. This graph represents an assessment of their R&D platform. Its dynamics depend entirely on the results of their clinical trials and partnerships with major pharma.
AKIMA Market Segment Index - Oncology targeted therapy
IDEAYA Biosciences (IDYA) is a clinical-stage biotech focused on Synthetic Lethality, a new approach in oncology (cancer). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does IDEAYA's breakthrough (but risky) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
IDEAYA is an oncology company specializing in synthetic lethality (destroying cancer cells through specific genetic vulnerabilities). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, fueled by trial data, compares to overall economic trends.
